Ganitumab
- Generic Name
- Ganitumab
- Drug Type
- Biotech
- CAS Number
- 905703-97-1
- Unique Ingredient Identifier
- CK1441RCZ8
- Background
Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Metastatic SarcomaRecurrent SarcomaResectable Sarcoma
- Interventions
- Device: Drug Delivery MicrodeviceProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04199026
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Palbociclib + Ganitumab In Ewing Sarcoma
- Conditions
- Ewing's Sarcoma RecurrentEwing Sarcoma
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04129151
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
- Conditions
- RhabdomyosarcomaRhabdomyosarcoma, EmbryonalRhabdomyosarcoma, Alveolar
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT03041701
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
- Conditions
- Ewing Sarcoma
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT03029481
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
- Conditions
- Metastatic Malignant Neoplasm in the Bone MarrowPeripheral Primitive Neuroectodermal Tumor of Soft TissuesMetastatic Ewing SarcomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the LungMetastatic Peripheral Primitive Neuroectodermal Tumor of Bone
- Interventions
- Radiation: External Beam Radiation TherapyRadiation: Stereotactic RadiosurgeryProcedure: Therapeutic Surgical Procedure
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 312
- Registration Number
- NCT02306161
- Locations
- 🇺🇸
Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States
🇺🇸Ann M Wierman MD LTD, Las Vegas, Nevada, United States
🇺🇸Flaget Memorial Hospital, Bardstown, Kentucky, United States
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
- Conditions
- PIK3CA Mutated Advanced Solid TumorsPIK3CA Amplified Advanced Solid Tumors
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT01708161
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
- Conditions
- Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT01562899
- Locations
- 🇺🇸
Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States
🇺🇸University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States
🇬🇧Pfizer Investigative Site, Sutton, Surrey, United Kingdom
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01479179
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
- Conditions
- UnresectableAdenocarcinoma of the PancreasLocally Advanced
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01318642
- Locations
- 🇬🇧
Guys Hospital, London, United Kingdom
🇬🇧Research Site, Preston, United Kingdom
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
- Conditions
- Adenocarcinoma of the PancreasAdvanced Solid TumorsCancerCancer of PancreasMetastatic Pancreatic CancerPancreas CancerCancer of the PancreasMetastasesMetastatic CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT01231347
- Locations
- 🇬🇧
Research Site, Northampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.